Human milk components the focus of partnership
Aug. 29, 2011
by Keith Nunes
MADISON, N.J. — Pfizer Nutrition, a business unit of Pfizer, Inc., has entered into a collaborative research agreement with Jennewein Biotechnologie, Rheinbreitbach, Germany, to develop and market two human milk oligosaccharides (H.M.O.s). The partnership will focus on enabling the functional and immunological benefits of H.M.O.s to become available to infants being fed with infant formulas.
“Building upon nearly a century as pioneers in infant nutritional science, we are constantly striving to more closely replicate the composition and functional benefits of breast milk, and this partnership truly helps further this mission,” said John Troup, vice-president of global research and development for Pfizer Nutrition.
Human milk oligosaccharides are a component of mother’s milk, and provide short- and long-term benefits to infants from birth onwards, according to the companies. Scientific research has shown that H.M.O.s may lower infants’ risk of infection during the time of lactation. In addition, the compounds are known to influence colonization of beneficial bacteria and support healthy immune development.
“Complex oligosaccharides in general and H.M.O.s in particular show an enormous potential for use in human nutrition,” said Stefan Jennewein, managing director and co-founder of Jennewein Biotechnologie. “The cooperation between Pfizer Nutrition and Jennewein Biotechnologie will accelerate the developments in this field by bringing together specific complementary competencies.”